BioNTech und Mitgründer kündigen Pläne für neues Mitgründer-geführtes Unternehmen zur Entwicklung von mRNA-Innovationen der nächsten Generation an, während BioNTech auf dem Weg zu einem Multi-Produkt-Unternehmen bis 2030 voranschreitet

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Binding agreement expected to be signed by end of first half of 2026

  60% confidence

• Now is the right time to prepare the handover of the baton

  60% confidence

• 2026 will be the first year the company expects multiple late-phase clinical trial data updates in various high-incidence cancer indications

  60% confidence

• BioNTech is now very well positioned to continue its mission and establish itself as a commercial biopharma company with multiple approved products

  60% confidence

• This plan can offer significant added value for both BioNTech and the new company, as it opens opportunities for both organizations to make meaningful contributions to patient benefit

  60% confidence

• BioNTech expects to maximize value for patients and shareholders through these plans

  60% confidence

• Vision has always been to translate science into progress for patients

  60% confidence

• BioNTech expects to have 15 ongoing Phase 3 oncology trials by end of 2026

  60% confidence

Data points we hold from this source